Business Wire

Sutherland and Celona Launch AI-Enabled Private 5G and Autonomous Network Solution for Enterprises and Service Providers Globally

12.11.2025 14:00:00 CET | Business Wire | Press Release

Share

In a move set to redefine how enterprises and service providers manage mission-critical connectivity, Sutherland, a global leader in business and digital transformation, today announced the launch of an AI-enabled Private 5G and Autonomous Network solution in collaboration with Celona, the Silicon Valley innovator that pioneered the 5G LAN architecture.

This end-to-end offering brings together Sutherland’s Agentic Service Management Orchestration (SMO) platform and suite of AI-enabled xApps and rApps with Celona’s next-generation private 5G infrastructure. The result is a self-managing, intent-based network that dramatically reduces human intervention while increasing performance, resilience, and sustainability across enterprise and telecom environments.

“Enterprises no longer want to manage networks — they want networks that manage themselves,” said Sriram Panchapakesan, Chief Executive Officer of Communications, Media & Entertainment, Sutherland. “By combining autonomy with intelligence, this solution gives communication service providers greater control, faster resolution, and the agility to evolve as demands change.”

Through this collaboration, Sutherland’s NetSentinel.AI and NetAssist.AI platforms integrate seamlessly with Celona’s edge and radio technologies, powered by Sutherland’s Agentic SMO and an extensive suite of AI-enabled x-Apps and r-Apps. Together, these capabilities enable intent-based automation, dynamic network slicing, and closed-loop quality-of-service assurance across the full network lifecycle.

This AI-powered solution delivers measurable improvements in uptime, performance, and operational efficiency, while reducing the total cost of ownership and accelerating the path toward fully autonomous, self-optimizing networks.

“We are excited to bring this joint solution to market with Sutherland,” said Rajeev Shah, Co-founder and Chief Executive Officer, Celona. “Our combined expertise in private 5G innovation and AI-driven network automation will accelerate the global adoption of autonomous networks that are more predictive, adaptive, and sustainable — powering a new era of industrial intelligence.”

From manufacturing floors and logistics hubs to healthcare systems and energy networks, this joint solution empowers organizations to deploy secure, reliable, high-performance connectivity. Available across North America, EMEA, APAC, and LATAM, Sutherland and Celona’s collaboration advances the industry’s path toward fully autonomous networks — simplifying operations, improving service continuity, and enabling enterprises to scale digital transformation responsibly and sustainably.

About Sutherland

Artificial Intelligence. Automation. Cloud Engineering. Advanced Analytics.
For Enterprises, these are key factors of success. For us, they’re our core expertise.

We work with global iconic brands. We bring them a unique value proposition through market-leading technologies and business process excellence. At the heart of it all is Digital Engineering – the foundation that powers rapid innovation and scalable business transformation.

We’ve created 363 unique and independent inventions, 250 of which are AI-based and rolled up under several patent grants in critical technologies. Leveraging our advanced products and platforms, we drive digital transformation at scale, optimize critical business operations, reinvent experiences, and pioneer new solutions, all provided through a seamless “as-a-service” model.

For each company, we provide new keys for their businesses, the people they work with, and the customers they serve. With proven strategies and agile execution, we don’t just enable change — we engineer digital outcomes.

Know more: www.sutherlandglobal.com

About Celona

Based in Silicon Valley, Celona is a pioneer and leading innovator of enterprise private wireless solutions. The company developed the industry’s first 5G LAN system, a turnkey private 5G solution that enables enterprises to meet growing demands for secure, reliable connectivity. Celona 5G LAN has been deployed globally across industries, supported by more than $135 million in venture funding from Lightspeed Venture Partners, Norwest Venture Partners, NTT Ventures, Cervin Ventures, DigitalBridge, and Qualcomm Ventures.
www.celona.io

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112408394/en/

Contacts

For further queries: mediarelations@sutherlandglobal.com
Know more: www.sutherlandglobal.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sutherlandg
lobal.com%2F&esheet=54356258&newsitemid=20251112408394&lan=en-US&anchor=www.suth
erlandglobal.com&index=5&md5=2df8722dee9a3c50bb4c6647a263f180

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye